Molecular Cancer Therapeutics Molecular Diagnostics in Cancer Therapeutic Development: Fulfilling the Promise of Personalized Medicine Bridging the Lab and the Clinic in Cancer Medicine
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sweeney, C. J.
Right arrow Articles by Nakshatri, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sweeney, C. J.
Right arrow Articles by Nakshatri, H.
Mol Cancer Ther. 2005;4:1004-1012
© 2005 American Association for Cancer Research

The sesquiterpene lactone parthenolide in combination with docetaxel reduces metastasis and improves survival in a xenograft model of breast cancer

Christopher J. Sweeney1, Sanjana Mehrotra2, Miral R. Sadaria3, Suresh Kumar3, Nicholas H. Shortle3, Yaritzabel Roman3, Carol Sheridan3, Robert A. Campbell3, Daryl J. Murry7, Sunil Badve2 and Harikrishna Nakshatri3,4,5,6

Departments of 1 Medicine, 2 Pathology, 3 Surgery, and 4 Biochemistry and Molecular Biology, 5 Walther Oncology Center, Indiana University School of Medicine; 6 Walther Cancer Institute, Indianapolis, Indiana; and 7 College of Pharmacy, The University of Iowa, Iowa City, Iowa

Requests for reprints: Harikrishna Nakshatri, R-202, Indiana Cancer Research Institute, 1044 West Walnut Street, Indianapolis, IN 46202. Phone: 317-278-2238; Fax: 317-274-0396. E-mail: hnakshat{at}iupui.edu


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Parthenolide, a sesquiterpene lactone, shows antitumor activity in vitro, which correlates with its ability to inhibit the DNA binding of the antiapoptotic transcription factor nuclear factor {kappa}B (NF-{kappa}B) and activation of the c-Jun NH2-terminal kinase. In this study, we investigated the chemosensitizing activity of parthenolide in vitro as well as in MDA-MB-231 cell–derived xenograft metastasis model of breast cancer. HBL-100 and MDA-MB-231 cells were used to measure the antitumor and chemosensitizing activity of parthenolide in vitro. Parthenolide was effective either alone or in combination with docetaxel in reducing colony formation, inducing apoptosis and reducing the expression of prometastatic genes IL-8 and the antiapoptotic gene GADD45ß1 in vitro. In an adjuvant setting, animals treated with parthenolide and docetaxel combination showed significantly enhanced survival compared with untreated animals or animals treated with either drug. The enhanced survival in the combination arm was associated with reduced lung metastases. In addition, nuclear NF-{kappa}B levels were lower in residual tumors and lung metastasis of animals treated with parthenolide, docetaxel, or both. In the established orthotopic model, there was a trend toward slower growth in the parthenolide-treated animals but no statistically significant findings were seen. These results for the first time reveal the significant in vivo chemosensitizing properties of parthenolide in the metastatic breast cancer setting and support the contention that metastases are very reliant on activation of NF-{kappa}B.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
Intrinsic or acquired resistance to chemotherapy is a major clinical problem. Several factors including expression levels of multidrug resistance genes, and proapoptotic and antiapoptotic genes determine the response to chemotherapy (1, 2). Antiapoptotic genes that determine response to chemotherapy include cIAP-1, cIAP-2, XIAP, TRAF-1, TRAF-2, Bcl-2, Bfl-1/A1, Bcl-xL, c-FLIP, and Mn-SOD (3, 4). The transcription factors nuclear factor {kappa}B (NF-{kappa}B), activator protein 1, and signal transducers and activators of transcription 3 are the major transcription factors that control the expression of antiapoptotic and proapoptotic genes that determine the sensitivity of cancer cells to therapy (2, 4, 5). Aberrant activation of these transcription factors, therefore, may lead to changes in antiapoptotic and proapoptotic gene threshold and resistance to chemotherapy.

NF-{kappa}B is an extracellular signal–activated transcription factor, which usually resides in the cytoplasm of resting cells due its association with inhibitor of {kappa}B proteins (3, 6). On exposure of cells to cytokines and growth factors such as interleukin (IL)-1, tumor necrosis factor (TNF), or epidermal growth factor, a series of signaling events trigger phosphorylation and degradation of inhibitors of {kappa}B. NF-{kappa}B, liberated from inhibitor of {kappa}B, translocates to the nucleus, binds specific response elements in the promoter region of target genes, and regulates gene expression (6). A distinct phosphorylation network controls subcellular distribution and/or activity of activator protein 1 and signal transducers and activators of transcription 3 transcription factors (7, 8).

Constitutive activation of NF-{kappa}B is observed in a number of cancers including breast cancer (3). It is likely that constitutively active NF-{kappa}B contributes to chemotherapeutic resistance by up-regulating the expression of antiapoptotic genes. Consistent with this possibility, we and others have observed that inhibition of NF-{kappa}B through either overexpression of inhibitors of {kappa}B or prior exposure to chemical inhibitors, such as parthenolide, sensitize cancer cells to chemotherapeutic drugs such as paclitaxel and CPT11 (9, 10).

Parthenolide is the major focus of this investigation. It is derived from the herb feverfew, which is being used for migraine prophylaxis (11). Apart from inhibiting NF-{kappa}B, parthenolide inhibits signal transducers and activators of transcription 3 activity (12, 13). Depending on the cell type, it can activate or repress c-Jun NH2-terminal kinase (JNK), which modulates the activity of activator protein 1 (14–16). We and others have shown the requirement of JNK activation in parthenolide-mediated sensitization of cancer cells to TNF and TNF-related apoptosis inducing ligand (15, 16). The ability of parthenolide to alter the function of three transcription factors makes it an ideal antitumor agent that can sensitize cancer cells to chemotherapy by reducing the level/activity of antiapoptotic proteins. Despite numerous studies showing antitumor activity in vitro, there are few in vivo studies with parthenolide (9, 16–18). In this report, we analyze the chemosensitizing properties of parthenolide in vitro and in a xenograft model of breast cancer focusing on its effects on NF-{kappa}B and cytokines and antiapoptotic proteins under its control.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Breast Cancer Cell Lines
MDA-MB-231 and HBL-100 cells were obtained from American Type Tissue Culture Collection (Rockville, MD) and grown in MEM plus 10% FCS (9).

In vitro Drug Treatment and Apoptosis Assays
Sensitivity of cells to parthenolide, docetaxel, or combination was measured by clonogenic assay (15). Briefly, cells (100 cells per well in six-well plates, assayed in triplicate) were treated with the indicated drugs for 24 hours. The drugs were removed, cells were washed, and fresh media was added. Number of colonies after 21 days of drug treatment was counted after staining with Giemsa stain. The amount of colony formation for the treated groups was expressed as a percentage of controls (relative colony formation). The carboxyfluorescein FLICA apoptosis detection kit (Immunohistochemistry Technologies, LLC, Bloomington, MN) was used to measure typical apoptosis, atypical apoptosis, and necrosis (19). Briefly, 2 x 105 cells grown overnight on a 60-mm plate were treated with indicated drugs for 48 hours. Both attached and floating cells were collected by trypsinization and incubated with carboxyfluorescein-labeled pan-caspase inhibitor carboxyfluorescein-benzyloxycarbonyl-valine-alanine-aspartic acid-fluoromethyl ketone for 2 hours at 37°C. Labeled cells were rinsed twice in PBS and resuspended in 300 µL of PBS containing 0.3 µg of propidium iodide. Apoptotic cells were identified by FACScan analysis as previously described (19). All apoptosis assays were done two to five times and representative data are presented in the text.

Northern Blot Analysis
Cells were treated with indicated drugs and RNA was isolated using RNAeasy kit from Qiagen Sciences (Valencia, CA). Northern blotting was done as previously described (20).

Mammary Fat Pad Injection of Tumor Cells and Treatment
MDA-MB-231 cells, which have been passed once through mammary fat pad (TMD231), were used for mammary fat pad injection because these cells formed tumors reproducibly and were metastatic. Cells, 106, were injected into the mammary fat pad of 6- to 7-week-old female nude mice. In the metastasis survival model, tumors (~100 mm3) were removed after 6 weeks and treatment was initiated a day after removal of the tumors and mice were assigned to each treatment group based on average tumor size and weight. Average weight of animals and size of tumors were similar among different groups. In the orthotopic model, the tumors were left in place and treatment commenced 14 days after cell implantation. In both experiments, parthenolide (40 mg/kg as a slurry in 10% ethanol) was given daily by oral gavage. Docetaxel (5 mg/kg in 13% ethanol) was given i.p. once weekly. Experiment was done thrice with 8 to 11 animals per treatment group in each experiment. Lungs, primary tumor regrowth, and/or blood was collected when the animals died or were sacrificed as per the advice of attending Veterinarian or at the end of the experiment. Mice were treated for up to 45 days after tumor removal in the metastasis survival model and the number of mice euthanized at this time point was scored. In the orthotopic mammary fat pad model, mice were treated for 6 weeks, starting 2 weeks after implantation when the tumors were established. The tumors were measured weekly with vernier calipers. Tumor volume was calculated using the following formula: sagittal dimension (mm) x [cross dimension (mm)]2 / 2, and expressed in cubic millimeter (21).

Analysis of Tumor, Lung, and Serum Samples
Lungs were analyzed for metastasis by H&E staining. Metastasis index was calculated as previously described (22). Briefly, the number and size of metastasis in two to five fields per sample were calculated and a score of 4+ was given to a sample with the highest metastasis and relative metastasis in other samples was calculated. LINCOplex multiplex immunoassay system (Linco Research, Inc., St. Charles, MO) was used to measure levels of cytokines in the serum and the samples were analyzed in duplicate.

Immunohistochemistry for p65
Sections, 4 µm in thickness, were deparaffinized and hydrated. Antigen retrieval was done in 140 mmol/L citrate buffer (pH 6.0) in a decloaking chamber (BioCare, Walnut Creek, CA) at 115°C for 3 minutes. The slides were then transferred to boiling deionized water and allowed to cool for 20 minutes at room temperature. The endogenous peroxidase activity was blocked by Peroxo-Block (Zymed, San Francisco, CA) for 2 minutes. The slides were then incubated with rabbit polyclonal p65 antibody (Lab Vision-NeoMarkers, Fremont, CA; diluted 1:100) for 3 hours at room temperature, washed in Optimax (Biogenex, San Ramon, CA), followed by incubation for 10 minutes with horseradish peroxidase polymer conjugate (Zymed). The stain was visualized using Dako liquid DAB plus substrate chromogen solution and hematoxylin QS (Vector Laboratories, Burlingame, CA) counterstain. Ten random microscopic fields were identified and the number of nuclei staining for p65 was documented and expressed as percent of total nuclei in the 10 fields. Nuclear counts were done using a hemocytometer counter.

Statistical Analysis
For the metastasis survival model, Prism 3 (version 3.02) for Windows (GraphPad Software, San Diego, CA) was used to generate a Kaplan-Meier survival curves. The log-rank test was then used to compare the survival of the parthenolide alone, docetaxel alone, and docetaxel plus parthenolide groups with the survival of the control group. All analyses used a two-sided P value. For the orthotopic mammary fat pad experiment, analysis was done using SAS Version 8 (Cary, NC). Tumor volume (mm3) was obtained from 80 mice (20 per group) treated in four treatment groups across eight time points. A linear growth curve model was fit using a mixed model with a variance-covariance model that incorporates correlations of observations within a cage and across time. To compare the rates of change of the tumor volume (mm3) between mice treated with parthenolide, docetaxel, parthenolide and docetaxel, and control, the slope estimates from the model were compared. No adjustment for multiple comparisons was made.

To statistically compare the results between groups of the lung metastasis index, nuclear NF-{kappa}B staining in tumor cells, and cytokine levels in the serum, the Kruskal-Wallis test (nonparametric ANOVA) with Dunn's post test for multiple comparisons was done using GraphPad InStat version 3.00 for Windows 95 (GraphPad Software). GraphPad program was also used for statistical analysis of clonogenic and apoptosis assay results.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
Parthenolide Increases the Sensitivity of Breast Cancer Cells to Docetaxel In vitro
Previous studies have shown that JNK increases whereas NF-{kappa}B reduces the sensitivity of cancer cells to docetaxel (23–25). Because parthenolide could induce JNK and decrease NF-{kappa}B in cell type–specific manner (15), we investigated whether parthenolide can increase sensitivity of breast cancer cells to docetaxel. We used clonogenic assay to determine the effect of parthenolide and docetaxel combination on HBL-100 and MDA-MB-231 cells. MDA-MB-231 cells correspond to most aggressive estrogen receptor {alpha}–negative breast cancer cells whereas HBL-100 cells are immortalized human breast epithelial cells with integrated SV40 DNA, although there are some doubts about the origin of these cells. A lower number of colonies were formed when cells were treated with combination of parthenolide and docetaxel compared with treatment with either drug (Fig. 1). A lower dose of either drug did not inhibit colony formation by MDA-MB-231 cells. Combination of parthenolide and docetaxel at this dose inhibited colony formation (P < 0.003). Drug combination was more effective than either drug at lower doses in inhibiting colony formation by HBL-100 cells (P = 0.0001).



View larger version (19K):
[in this window]
[in a new window]
  		Figure 1. Chemosensitizing activity of parthenolide in vitro. Parthenolide increases sensitivity of HBL-100 and MDA-MB-231 cells to docetaxel as measured by clonogenic assay. HBL-100 and MDA-MB-231 cells (100 cells per well in triplicate in six-well plates) were exposed to indicated drugs for 24 h. The number of colonies was counted after 21 d and reported as relative colony formation (percentage of control). For HBL-100 cells, P < 0.05 for control versus either drug or combination and either drug versus combination, except for docetaxel versus combination at higher dose (P = 0.224). For MDA-MB-231 cells, at lower dose either drug was ineffective but the combination was effective in reducing colony number (P = 0.002).

 
Parthenolide and Docetaxel Combination Enhances Atypical Apoptosis of Cancer Cells
We used carboxyfluorescein FLICA to measure apoptosis of drug-treated cells (15). This assay simultaneously measures cells undergoing typical apoptosis, atypical apoptosis (apoptosis with loss of plasma membrane integrity), and necrosis. However, this assay is not as sensitive as clonogenic assay, thus requiring higher concentration of drugs to detect apoptosis. Docetaxel (5 nmol/L), but not parthenolide (2 µmol/L), induced atypical apoptosis of HBL-100 cells (Fig. 2A). Atypical apoptosis was further enhanced in cells treated with both parthenolide and docetaxel. Total apoptosis/atypical apoptosis/necrosis is shown in Table 1. Parthenolide treatment alone caused apoptosis of MDA-MB-231 cells (Fig. 2B). Cells treated with both parthenolide and docetaxel displayed elevated levels of atypical apoptosis. Thus, increased cell death observed in cells treated with a combination of parthenolide and docetaxel is mostly due to a shift in cell death from typical apoptosis to atypical apoptosis.



View larger version (41K):
[in this window]
[in a new window]
  		Figure 2. The effect of parthenolide and docetaxel on apoptosis of HBL-100 and MDA-MB-231 cells. Apoptosis was measured using carboxyfluorescein FLICA as described in Materials and Methods. X-axis, propidium iodide staining; Y-axis, active caspase staining. Bottom left, live cells; top left, apoptotic cells; top right, atypical apoptotic cells; bottom right, necrotic cells.

 

View this table:
[in this window]
[in a new window]
  		Table 1. Parthenolide and docetaxel–induced apoptosis/necrosis of HBL-100 and MDA-MB-231 cells

 
Parthenolide and Docetaxel Combination Is Effective in Enhancing Survival and Reducing Metastases in a Xenograft Model of Breast Cancer
To determine whether parthenolide and docetaxel combination is effective in an in vivo metastasis model, we used MDA-MB-231 xenograft model to examine the effect of drugs in an adjuvant setting. In this series of experiments, primary tumors were surgically removed when tumors reached ~100 mm3 (~6 weeks after implantation) and treatment was initiated a day after surgery. We have observed that surgical removal of primary tumor is necessary to detect metastasis and terminal progression of disease in this model. Experiments were done thrice with 8 to 12 animals per treatment group in each experiment. The 30-day survival data from the first two experiments, in which docetaxel was given at 5 mg/kg once a week and parthenolide at 40 mg/kg daily, are shown in Fig. 3A. It is notable that the in the two experiments, the average number of mice alive at 30 days was ~60% in control, docetaxel, and parthenolide (Fig. 3A). However, the average number of mice alive for the combination arm in both experiments was 90%. The unpaired Student's t test with a two-sided P value showed that this was statistically significant (P = 0.0489). For the long-term survival analysis with mice treated until 45 days after tumor removal, a Kaplan-Meier survival curve was generated and is shown in Fig. 3B. Animals treated with docetaxel and parthenolide showed significantly enhanced survival with 90% of mice alive at day 45 compared with 73% (8 of 11) in the docetaxel alone arm, 64% (7 of 11) in the parthenolide arm, and 34% (4 of 11) in the control arm. The improvement in overall survival in the combination arm was found to be statistically significant (log-rank test, two-sided P = 0.0171). It should also be noted that the survival of animals treated with docetaxel alone or parthenolide alone was not statistically significantly different from control animals but was numerically better. Taken together, these results indicate that parthenolide, when given daily at the doses described, can function as a chemosensitizer in vivo.



View larger version (16K):
[in this window]
[in a new window]
  		Figure 3. The effect of parthenolide and docetaxel treatment on survival in a metastasis xenograft model. A, 30-day survival rate from two experiments (n = 20–24). B, long-term survival analysis (n = 10–11). Tumor cell implantation, surgery, and treatment protocol are described in Materials and Methods.

 
We did H&E staining of lungs to determine whether enhanced survival in animals treated with parthenolide plus docetaxel correlates with reduced lung metastasis. A representative staining pattern of lungs from untreated and treated animals is shown in Fig. 4A. Metastasis index is presented in Fig. 4B. Metastasis was lower in animals treated with parthenolide or docetaxel with further reduction in animals treated with parthenolide and docetaxel. These results show a direct correlation between reduced metastasis and enhanced survival. However, although there was a numerical difference, there was no statistical difference (P = 0.19).



View larger version (80K):
[in this window]
[in a new window]
  		Figure 4. Metastasis index in untreated and drug-treated animals. A, H&E staining of lungs of control and treated animals. Metastasis is lower in animals treated with docetaxel and parthenolide combination compared with untreated or single drug–treated animals. B, lung metastasis index in untreated, docetaxel-treated, parthenolide-treated, and parthenolide plus docetaxel–treated animals. P = 0.19.

 
The ability of parthenolide, docetaxel, and the combination to inhibit NF-{kappa}B DNA binding in vivo was assessed by two methods. The amount of NF-{kappa}B DNA binding in tumors that recurred in the mammary fat pad was quantified by determining the number of cells in a high power field (400x) that had nuclear staining. A representative staining pattern is shown in Fig. 5A. Five areas per tumor were analyzed; four animals in the control, docetaxel, and combination arms and three in the combination arm had suitable tumors for analysis. The number decreased from 21.15 in control to 13.4 and 13.6 in docetaxel and parthenolide, respectively (P >= 0.2, single agent versus control) and 10.85 for the combination (P < 0.01, versus control; Fig. 5B).



View larger version (117K):
[in this window]
[in a new window]
  		Figure 5. Effect of parthenolide and docetaxel treatment on nuclear NF-{kappa}B staining. A, representative immunohistochemistry of primary tumors from untreated and drug-treated animals. Arrows, cancer cells with nuclear p65. B, nuclear p65 in primary tumors of various treatment groups. P < 0.01, control versus combination. C, nuclear staining pattern in lung metastatic tissue. P < 0.01, control versus combination. Detailed calculation of nuclear p65 is described in Materials and Methods.

 
For lung metastases deposits, of every 100 tumor cells seen at 400 x, the number of cells to have NF-{kappa}B nuclei staining was calculated. The metastatic deposits were randomly identified and the average was 16.6 in control, 12 in docetaxel, 9.1 in parthenolide, and 0.66 in the combination (Fig. 5C). Only the combination was statistically significantly different from control (P < 0.01).

Efficacy of Parthenolide in Orthotopic Mammary Fat Pad Model
To determine the effect of parthenolide, alone or in combination with docetaxel, on primary tumor growth, we treated animals implanted with MDA-MB-231 cells into the mammary fat pad. After 42 days of therapy, docetaxel reduced tumor growth by 15% versus control whereas parthenolide and the combination were more effective as growth was reduced by 25% and 29%, respectively, in this chemoresistant model (Fig. 6). A linear growth curve model was fit using a mixed model with a variance-covariance model that incorporates correlations of observations across time. The rate of change of tumor volume between treatment groups was evaluated by comparing the slope estimates from the model. The rate of change for parthenolide versus control was –1.52 (P = 0.057), that for docetaxel versus control was –1.3 (P = 0.11), and for combination –0.86 (P = 0.28). As such, there was a trend toward slower tumor growth in the parthenolide-treated animals but it did not enhance the activity of docetaxel (as was seen in the metastasis survival model). These results are consistent with a recent observation that NF-{kappa}B plays a role in the growth of cancer cells at sites of metastasis but not at primary sites in breast cancer (26).



View larger version (22K):
[in this window]
[in a new window]
  		Figure 6. Efficacy of parthenolide in orthotopic mammary fat pad model. Tumor growth rate in control and treated animals is shown (n = 20 per arm).

 
Animals Treated with Parthenolide and Docetaxel Show Reduced Levels of IFN{gamma} and TNF{alpha} but not IL-6 in Serum
To test the significance of docetaxel, parthenolide, and the combination on the ability to decrease NF-{kappa}B activity in vivo, we measured the level of mouse cytokines in the serum. Cytokines measured were IL-1ß, IL-2, IL-6, IL-10, TNF{alpha}, and IFN{gamma}. It should be pointed out that IL-1ß, IL-6, TNF{alpha}, and IFN{gamma} are NF-{kappa}B–inducible genes (27, 28). IL-1ß was undetectable. There was no difference in the levels of IL-2, IL-6, and IL-10 (Fig. 7 and data not shown). In contrast, IFN{gamma} was lower in animals treated with parthenolide or docetaxel (P >= 0.2, by Kruskal-Wallis test) with further reduction to a statistically significant degree in animals treated with both drugs (P < 0.05; Fig. 7). Both docetaxel and parthenolide reduced TNF{alpha} levels with no further reduction in animals treated with both drugs (Fig. 7). The level of reduction did not reach statistical significance. Nonetheless, these results suggest that parthenolide can reduce the levels of cytokines induced by NF-{kappa}B in vivo with a greater suppression seen when given with docetaxel. Reduction in these cytokine levels is unrelated to tumor burden because the assay measured only mouse cytokines. Reduction of IFN{gamma} and TNF{alpha} in the serum of animals treated with docetaxel was surprising but consistent with the observation that docetaxel decreased anti–NF-{kappa}B activity in vivo. These results reveal a unique function for docetaxel in vivo. In addition, the result suggests that parthenolide can inhibit NF-{kappa}B activity in vivo and that the combination is able to decrease NF-{kappa}B activity even further.



View larger version (20K):
[in this window]
[in a new window]
  		Figure 7. Serum levels of IL-6, TNF, and IFN in untreated and drug-treated animals. Serum is from animals in metastasis model and the serum cytokines were measured using LINCOplex ELISA. *, statistically significant difference between treatment and control. TNF{alpha} and IL-6 levels did not show statistically significant difference.

 
Parthenolide Reduces IL-8 Expression In vitro
Metastasis of MDA-MB-231 cells in xenograft model requires IL-8 and/or CXCR4 (29, 30). In addition, IL-8 is involved in chemotherapy-resistant growth of cancer cells (31). Urokinase-type plasminogen activator is also involved in metastasis of MDA-MB-231 cells (32). All of these genes are regulated by NF-{kappa}B (26, 27, 33). Transforming growth factor ß1 (TGFß1) is also suggested to play a role in metastasis of these cells (30). JNK has been shown to suppress TGFß1 expression and parthenolide induces JNK (34). We have previously shown repression of CXCR4 expression by parthenolide in these cells but the effect of parthenolide on IL-8 or TGFß1 has not been reported (33). Because LINCOplex ELISA was not sensitive enough to identify cancer cell–derived human IL-8 in serum of animals (there is no mouse IL-8 counterpart), we determined whether parthenolide inhibits IL-8 expression in vitro. Parthenolide reduced IL-8 expression in the absence or presence of docetaxel (Fig. 8). TGFß1 expression was transiently reduced by parthenolide. For unknown reason, parthenolide did not block TGFß1 expression in the presence of docetaxel. Parthenolide had no effect on urokinase-type plasminogen activator expression.



View larger version (44K):
[in this window]
[in a new window]
  		Figure 8. Parthenolide inhibits IL-8 and TGFß1 expression in MDA-MB-231 cells in vitro. MDA-MB-231 cells were treated with parthenolide (5 µmol/L) either alone or in combination with docetaxel (5 nmol/L) for the indicated time. IL-8, TGFß1, urokinase-type plasminogen activator (uPA), and GADD45ß expressions were measured by Northern blot. The same blot was reprobed with 36B4, a ribosomal protein gene, to ensure equal loading.

 
Among antiapoptotic genes, we have previously shown inhibition of Mn-SOD by parthenolide (9). We observed modest inhibition of cIAP-2 but not of Bcl-xL by parthenolide (data not shown). Parthenolide had no effect on the expression of XIAP (15) and did not influence cleavage of XIAP by docetaxel (data not shown). Similarly, although parthenolide induced posttranslational modification of Bid as we previously reported (15), this modification had no effect on docetaxel-induced cleavage of Bid (data not shown). Interestingly, parthenolide reduced expression of GADD45ß, a NF-{kappa}B–regulated antiapoptotic gene that reduces apoptosis through inhibition of JNK (ref. 35; Fig. 8). Thus, parthenolide inhibits the expression of some but not all prometastatic and antiapoptotic genes regulated by NF-{kappa}B.


   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
In this report, we show the chemosensitizing properties of parthenolide in vitro and in vivo in an adjuvant metastasis model. Although previous studies have shown antitumor activity of parthenolide in vitro, in vivo antitumor activity has not been studied. Unlike the results of in vitro studies, parthenolide as a single agent had at most a modicum amount of activity in vivo. However, it is worth noting that its efficacy as a single agent equated to that of docetaxel at the doses and schedule used in these studies. Although we have not well characterized the pharmacokinetics of parthenolide, the dose given to mice was sufficient for reducing the expression of NF-{kappa}B–inducible genes and restricting the p65 subunit of NF-{kappa}B to the cytoplasm of tumor cells in vivo. Thus, the slight single-agent activity of parthenolide in vivo suggests that minimal inhibition of NF-{kappa}B activity alone is not sufficient for significant antitumor activity. Nonetheless, the dose given was sufficient for it to function as a chemosensitizing agent in the metastasis model and cause significant decrease in NF-{kappa}B nuclear localization and activity. The fact that two analyses across two different experiments—(a) comparison of 30-day survival from two experiments and (b) the overall survival at 45 days—showed significant results strongly supports this conclusion. This very interesting and unique finding is supported by the recent data showing exquisite dependence of breast cancer metastases, but not of primary tumor growth, on NF-{kappa}B (26).

Although constitutive NF-{kappa}B activation is reported in a variety of cancers (36, 37), its role in specific stages of cancer progression is just beginning to be defined. For example, recent studies suggest the requirement of NF-{kappa}B in tumor promotion of the colitis-associated cancer and the malignant phenotype of squamous cell carcinoma (38, 39). In contrast, NF-{kappa}B is not required in the early phases of hepatocyte transformation but is required for progression to hepatocellular carcinoma (40). Our study and a study by Huber et al. (26) suggest the requirement of NF-{kappa}B in metastasis but not in proliferation of breast cancer cells at primary sites. Thus, anti-NF-{kappa}B–based therapies may have cancer type–specific effects.

We observed two distinct effects of parthenolide in vivo: reducing metastasis and increasing the sensitivity to docetaxel. Reduced metastasis in parthenolide-treated animals may be a result of reduced IFN{gamma} production. IFN{gamma} has been shown to reduce the growth of primary breast cancers but increases metastasis (41). Similarly, lower levels of TNF{alpha} in parthenolide-treated animals may have resulted in reduced growth of cancer cells at sites of metastasis. TNF{alpha} level is elevated in the serum of patients with lymph node–positive breast cancer and it is believed to play a role in angiogenesis (42, 43).

Other possible parthenolide targets that play a role in reducing metastasis include IL-8, TGFß1, and CXCR4 (Fig. 8).

Exactly how parthenolide sensitizes to docetaxel in vivo is not known but may involve direct modulation of antiapoptotic gene expression or is a consequence of reduced prometastatic gene expression under NF-{kappa}B control. MDA-MB-231 cells used in this study express very high levels of NF-{kappa}B–regulated antiapoptotic genes, including Bcl-xL, TRAF-1, cIAP-2, and Mn-SOD, compared with breast cancer cells that lack constitutively active NF-{kappa}B (9). With the exception of Mn-SOD and cIAP-2, to a lesser extent, parthenolide had minimum effect on the expression of these genes (data not shown). In this study, we have identified GADD45ß, an antiapoptotic gene, as a target of parthenolide. Others have shown regulation of proapoptotic proteins Bax and Bak by parthenolide (44). Thus, the chemosensitizing activity of parthenolide could be secondary to reduced expression levels of select antiapoptotic genes. Alternatively, the chemosensitizing action of parthenolide may be an indirect consequence of repression of CXCR4, IL-8, and TGFß1 expressions. These genes have been shown to modulate antiapoptotic gene expression, apart from playing a role in metastasis (31, 45–47).

Docetaxel is a very important therapy for breast cancer as single agent or in combination with other agents (48, 49). However, docetaxel resistance is observed clinically. Our studies showing the beneficial effects of the docetaxel and parthenolide combination in an adjuvant setting in an animal model raise the hope for a similar combination treatment of docetaxel-resistant breast cancers. We have not observed any apparent toxicity in animals treated with parthenolide alone or in combination with docetaxel even after 10 weeks of continuous treatment. Additional preclinical studies in a syngeneic model may be required to confirm the effectiveness as well as the lack of toxicity of the combination treatment before our studies can be translated to clinic. The other major issue to resolve is improvement in the solubility and bioavailability of parthenolide. Poor solubility prevented us from dosing animals at more than 40 mg/kg of parthenolide. Preliminary pharmacokinetic studies have shown low nanomolar concentrations of parthenolide (~200 nmol/L; data not shown) in serum of treated animals, well below the target plasma concentrations of 5 µmol/L that we were aiming for based on our in vitro data. Efforts to make analogues with better bioavailability but maintaining the same degree of activity are under way. It is also of note that viable cancer cells were seen despite low amounts of NF-{kappa}B after treatment with docetaxel and parthenolide. This probably indicates that other survival pathways are important and that combining parthenolide derivatives with improved pharmacologic properties with other agents that block survival pathways will be needed.


   Acknowledgments
 
We thank Joan Dunn for technical assistance.


   Footnotes
 
Grant support: American Institute for Cancer Research grants 00A047 and 03A069-REN and grants-in-aid from Aventis Pharmaceuticals (H. Nakshatri) and National Cancer Institute grant CA37403 (S. Badve).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Note: H. Nakshatri is a Marian J. Morrison Investigator in Breast Cancer Research.

Received 1/31/05; revised 3/26/05; accepted 4/11/05.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: a link between cancer genetics and chemotherapy. Cell 2002;108:153–64.[CrossRef][Medline]
  2. Pommier Y, Sordet O, Antony S, Hayward RL, Kohn KW. Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks. Oncogene 2004;23:2934–49.[CrossRef][Medline]
  3. Baldwin AS. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-{kappa}B. J Clin Invest 2001;107:241–6.[CrossRef][Medline]
  4. Karin M, Lin A. NF-{kappa}B at the crossroads of life and death. Nat Immunol 2002;3:221–7.[CrossRef][Medline]
  5. Darnell JE Jr. Transcription factors as targets for cancer therapy. Nat Rev Cancer 2002;2:740–9.[CrossRef][Medline]
  6. Ghosh S, May MJ, Kopp EB. NF-{kappa}B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 1998;16:225–60.[CrossRef][Medline]
  7. Shaulian E, Karin M. AP-1 as a regulator of cell life and death. Nat Cell Biol 2002;4:E131–6.
  8. Levy DE, Darnell JE Jr. Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol 2002;3:651–62.[CrossRef][Medline]
  9. Patel NM, Nozaki S, Shortle NH, et al. Paclitaxel sensitivity of breast cancer cells with constitutively active NF-{kappa}B is enhanced by I{kappa}B{alpha} super-repressor and parthenolide. Oncogene 2000;19:4159–69.[CrossRef][Medline]
  10. Wang CY, Cusack JC Jr., Liu R, Baldwin AS Jr. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-{kappa}B. Nat Med 1999;5:412–7.[CrossRef][Medline]
  11. Murphy JJ, Heptinstall S, Mitchell JR. Randomised double-blind placebo-controlled trial of feverfew in migraine prevention. Lancet 1988;2:189–92.[Medline]
  12. Hehner SP, Hofmann TG, Droge W, Schmitz ML. The antiinflammatory sesquiterpene lactone parthenolide inhibits NF-{kappa}B by targeting the I{kappa}B kinase complex. J Immunol 1999;163:5617–23.[Abstract/Free Full Text]
  13. Sobota R, Szwed M, Kasza A, Bugno M, Kordula T. Parthenolide inhibits activation of signal transducers and activators of transcription (STATs) induced by cytokines of the IL-6 family. Biochem Biophys Res Commun 2000;267:329–33.[CrossRef][Medline]
  14. Won YK, Ong CN, Shi X, Shen HM. Chemopreventive activity of parthenolide against UVB-induced skin cancer and its mechanisms. Carcinogenesis 2004;25:1449–58.[Abstract/Free Full Text]
  15. Nakshatri H, Rice SE, Bhat-Nakshatri P. Antitumor agent parthenolide reverses resistance of breast cancer cells to tumor necrosis factor-related apoptosis-inducing ligand through sustained activation of c-Jun N-terminal kinase. Oncogene 2004;23:7330–44.[CrossRef][Medline]
  16. Zhang S, Lin ZN, Yang CF, Shi X, Ong CN, Shen HM. Suppressed NF-{kappa}B and sustained JNK activation contribute to the sensitization effect of parthenolide to TNF-{alpha}-induced apoptosis in human cancer cells. Carcinogenesis 2004;25:2191–9.[Abstract/Free Full Text]
  17. deGraffenried LA, Chandrasekar B, Friedrichs WE, et al. NF-{kappa}B inhibition markedly enhances sensitivity of resistant breast cancer tumor cells to tamoxifen. Ann Oncol 2004;15:885–90.[Abstract/Free Full Text]
  18. Wen J, You KR, Lee SY, Song CH, Kim DG. Oxidative stress-mediated apoptosis. The anticancer effect of the sesquiterpene lactone parthenolide. J Biol Chem 2002;277:38954–64.[Abstract/Free Full Text]
  19. Pozarowski P, Halicka DH, Darzynkiewicz Z. NF-{kappa}B inhibitor sesquiterpene parthenolide induces concurrently atypical apoptosis and cell necrosis: difficulties in identification of dead cells in such cultures. Cytometry 2003;54A:118–24.
  20. Bhat-Nakshatri P, Campbell RA, Patel NM, et al. Tumour necrosis factor and PI3kinase control oestrogen receptor {alpha} protein level and its transrepression function. Br J Cancer 2004;90:853–9.[Medline]
  21. Kumar S, Kishimoto H, Chua HL, et al. Interleukin-1 {alpha} promotes tumor growth and cachexia in MCF-7 xenograft model of breast cancer. Am J Pathol 2003;163:2531–41.[Abstract/Free Full Text]
  22. Muller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001;410:50–6.[CrossRef][Medline]
  23. Kim R, Ohi Y, Inoue H, Toge T. Enhancement of chemotherapeutic agents induced-apoptosis associated with activation of c-Jun N-terminal kinase 1 and caspase 3 (CPP32) in bax-transfected gastric cancer cells. Anticancer Res 2000;20:439–44.[Medline]
  24. Wang Q, Wieder R. All-trans retinoic acid potentiates Taxotere-induced cell death mediated by Jun N-terminal kinase in breast cancer cells. Oncogene 2004;23:426–33.[CrossRef][Medline]
  25. Zhang H, Morisaki T, Nakahara C, et al. PSK-mediated NF-{kappa}B inhibition augments docetaxel-induced apoptosis in human pancreatic cancer cells NOR-P1. Oncogene 2003;22:2088–96.[CrossRef][Medline]
  26. Huber MA, Azoitei N, Baumann B, et al. NF-{kappa}B is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. J Clin Invest 2004;114:569–81.[CrossRef][Medline]
  27. Baeuerle PA, Henkel T. Function and activation of NF-{kappa}B in the immune system. Annu Rev Immunol 1994;12:141–79.[Medline]
  28. Sica A, Dorman L, Viggiano V, et al. Interaction of NF-{kappa}B and NFAT with the interferon-{gamma} promoter. J Biol Chem 1997;272:30412–20.[Abstract/Free Full Text]
  29. Bendre MS, Gaddy-Kurten D, Mon-Foote T, et al. Expression of Interleukin 8 and not Parathyroid Hormone-related Protein by Human Breast Cancer Cells Correlates with Bone Metastasis In vivo. Cancer Res 2002;62:5571–9.[Abstract/Free Full Text]
  30. Kang Y, Siegel PM, Shu W, et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003;3:537–49.[CrossRef][Medline]
  31. De Larco JE, Wuertz BR, Manivel JC, Furcht LT. Progression and enhancement of metastatic potential after exposure of tumor cells to chemotherapeutic agents. Cancer Res 2001;61:2857–61.[Abstract/Free Full Text]
  32. Kim J, Yu W, Kovalski K, Ossowski L. Requirement for specific proteases in cancer cell intravasation as revealed by a novel semiquantitative PCR-based assay. Cell 1998;94:353–62.[CrossRef][Medline]
  33. Helbig G, Christopherson KW II, Bhat-Nakshatri P, et al. NF-{kappa}B promotes breast cancer cell migration and metastasis by inducing the expression of the chemokine receptor CXCR4. J Biol Chem 2003;278:21631–8.[Abstract/Free Full Text]
  34. Ventura JJ, Kennedy NJ, Flavell RA, Davis RJ. JNK regulates autocrine expression of TGF-ß1. Mol Cell 2004;15:269–78.[CrossRef][Medline]
  35. De Smaele E, Zazzeroni F, Papa S, et al. Induction of gadd45ß by NF-{kappa}B downregulates pro-apoptotic JNK signalling. Nature 2001;414:308–13.[CrossRef][Medline]
  36. Karin M, Cao Y, Greten FR, Li ZW. NF-{kappa}B in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2002;2:301–10.[CrossRef][Medline]
  37. Nakshatri H, Goulet RJ Jr. NF-{kappa}B and breast cancer. Curr Probl Cancer 2002;26:282–309.[CrossRef][Medline]
  38. Greten FR, Eckmann L, Greten TF, et al. IKKß links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004;118:285–96.[CrossRef][Medline]
  39. Loercher A, Lee TL, Ricker JL, et al. Nuclear factor-{kappa}B is an important modulator of the altered gene expression profile and malignant phenotype in squamous cell carcinoma. Cancer Res 2004;64:6511–23.[Abstract/Free Full Text]
  40. Pikarsky E, Porat RM, Stein I, et al. NF-{kappa}B functions as a tumour promoter in inflammation-associated cancer. Nature 2004;431:461–6.[CrossRef][Medline]
  41. Lollini PL, Bosco MC, Cavallo F, et al. Inhibition of tumor growth and enhancement of metastasis after transfection of the {gamma}-interferon gene. Int J Cancer 1993;55:320–9.[Medline]
  42. Sheen-Chen SM, Chen WJ, Eng HL, Chou FF. Serum concentration of tumor necrosis factor in patients with breast cancer. Breast Cancer Res Treat 1997;43:211–5.[CrossRef][Medline]
  43. Leek RD, Landers R, Fox SB, Ng F, Harris AL, Lewis CE. Association of tumour necrosis factor {alpha} and its receptors with thymidine phosphorylase expression in invasive breast carcinoma. Br J Cancer 1998;77:2246–51.[Medline]
  44. Zhang S, Ong CN, Shen HM. Involvement of proapoptotic Bcl-2 family members in parthenolide-induced mitochondrial dysfunction and apoptosis. Cancer Lett 2004;211:175–88.[CrossRef][Medline]
  45. Balkwill F. Cancer and the chemokine network. Nat Rev Cancer 2004;4:540–50.[CrossRef][Medline]
  46. Abdollahi T, Robertson NM, Abdollahi A, Litwack G. Identification of interleukin 8 as an inhibitor of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in the ovarian carcinoma cell line OVCAR3. Cancer Res 2003;63:4521–6.[Abstract/Free Full Text]
  47. Teicher BA. Malignant cells, directors of the malignant process: role of transforming growth factor-ß. Cancer Metastasis Rev 2001;20:133–43.[CrossRef][Medline]
  48. Nowak AK, Wilcken NR, Stockler MR, Hamilton A, Ghersi D. Systematic review of taxane-containing versus non-taxane-containing regimens for adjuvant and neoadjuvant treatment of early breast cancer. Lancet Oncol 2004;5:372–80.[CrossRef][Medline]
  49. Yardley DA. Gemcitabine and docetaxel in metastatic and neoadjuvant treatment of breast cancer. Semin Oncol 2004;31:37–44.



This article has been cited by other articles:


Home page
 Cancer Res.Home page
G. Chakraborty, S. Jain, and G. C. Kundu
Osteopontin Promotes Vascular Endothelial Growth Factor Dependent Breast Tumor Growth and Angiogenesis via Autocrine and Paracrine Mechanisms
Cancer Res., January 1, 2008; 68(1): 152 - 161.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
N. K. Prasad, M. Tandon, S. Badve, P. W. Snyder, and H. Nakshatri
Phosphoinositol phosphatase SHIP2 promotes cancer development and metastasis coupled with alterations in EGF receptor turnover
Carcinogenesis, January 1, 2008; 29(1): 25 - 34.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. L. Guzman, R. M. Rossi, S. Neelakantan, X. Li, C. A. Corbett, D. C. Hassane, M. W. Becker, J. M. Bennett, E. Sullivan, J. L. Lachowicz, et al.
An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells
Blood, December 15, 2007; 110(13): 4427 - 4435.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
X. Fonrose, F. Ausseil, E. Soleilhac, V. Masson, B. David, I. Pouny, J.-C. Cintrat, B. Rousseau, C. Barette, G. Massiot, et al.
Parthenolide Inhibits Tubulin Carboxypeptidase Activity
Cancer Res., April 1, 2007; 67(7): 3371 - 3378.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Y. Kishida, H. Yoshikawa, and A. Myoui
Parthenolide, a Natural Inhibitor of Nuclear Factor-{kappa}B, Inhibits Lung Colonization of Murine Osteosarcoma Cells
Clin. Cancer Res., January 1, 2007; 13(1): 59 - 67.
[Abstract] [Full Text] [PDF]

Home page
 Integr Cancer TherHome page
M. F. McCarty and K. I. Block
Preadministration of High-Dose Salicylates, Suppressors of NF-{kappa}B Activation, May Increase the Chemosensitivity of Many Cancers: An Example of Proapoptotic Signal Modulation Therapy.
Integr Cancer Ther, September 1, 2006; 5(3): 252 - 268.
[Abstract] [PDF]

Home page
 CarcinogenesisHome page
Y.-K. Won, C.-N. Ong, and H.-M. Shen
Parthenolide sensitizes ultraviolet (UV)-B-induced apoptosis via protein kinase C-dependent pathways
Carcinogenesis, December 1, 2005; 26(12): 2149 - 2156.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sweeney, C. J.
Right arrow Articles by Nakshatri, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sweeney, C. J.
Right arrow Articles by Nakshatri, H.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research